Clinical Trial

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study is designed for multi-center,randomized,double-masked,active-contralled study to evaluate effective and security of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-25; most recent amendment 2025-03-11.
Status change: Recruiting → Active, Not Recruiting 2025-03-11
Status change: Not Yet Recruiting → Recruiting 2023-12-25
Trial Details
NCT Number NCT05972473
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Neovascular Age-related Macular Degeneration
Enrollment 600 participants
Start Date 2023-09-21
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-13